Medically Reviewed By:

Dr. Ahmed Farhan MBBS, FCPS (Internal Medicine) | Assistant Professor of Medicine | Consultant Physician | Specialist in Diabetes, Weight Management & Lifestyle Medicine Founder of Dibesity | Advocate of Evidence-Based Natural Health

A worry that a lot of people share right now

If you take a GLP-1 drug like Ozempic, Wegovy, Zepbound, or Mounjaro — or you’re thinking about it — you may have seen headlines warning that these drugs “eat your muscle.”

It’s a scary idea. Muscle keeps you strong, keeps you steady on your feet, and, as it turns out, plays a much bigger role in your blood sugar than most people realize.

So is the worry real? The honest answer is: it’s complicated, doctors are still arguing about it, and the size of the problem depends a lot on who you are.

Here’s what the research actually shows — and why muscle matters for your blood sugar whether or not you ever take one of these drugs.

Why this is such a big topic right now

Millions of people are now taking GLP-1 drugs for weight loss or type 2 diabetes. As more people use them, doctors have gotten a much closer look at what happens to the body during rapid weight loss — not just the fat that comes off, but everything else that comes off with it.

At the 2026 American Diabetes Association conference, two well-known obesity researchers held a public debate on this exact question.

One argued that most of the weight lost on these drugs is fat, not muscle, and that there’s no solid proof the drugs cause frailty or muscle-wasting disease.

The other agreed the overall risk looks small for most people, but said certain groups — especially older adults who start with less muscle — deserve closer attention.

That kind of open disagreement among experts is a sign this is a genuinely unsettled question, not settled science being ignored.

What the latest research says

Several research teams have looked at body scans from people taking semaglutide, tirzepatide, and liraglutide during clinical trials.

Across these studies, somewhere between about one-tenth and nearly half of the total weight lost was lean tissue — a category that includes muscle, but also organs, water, and other non-fat tissue. That’s a wide range, and it depends on the drug, the dose, and how the study measured “lean tissue.”

A 2026 study published in Cell Reports Medicine, which combined lab experiments in mice with a small human trial, added an important detail.

It found that GLP-1 drugs did reduce the total amount of muscle mass, but the proportion of the body that was made of muscle actually went up — because even more fat was lost.

In the mice, this didn’t come with a loss of physical performance. In fact, running ability improved. The liver, not the muscle, lost the largest share of lean tissue in that study.

A separate review of dozens of clinical trials reached a similar middle-ground conclusion: yes, some muscle is lost, but for most people it happens in roughly the same proportion as with any other kind of major weight loss — including weight-loss surgery, which doctors have safely managed for decades without treating it as an emergency.

What kind of evidence is this? Mostly clinical trial data and one early mechanistic study — solid, but still developing. Nobody has run the long-term study that would settle exactly who is truly at risk and by how much.

What researchers actually found

Putting the pieces together, three things seem to be true at the same time:

Muscle loss during GLP-1 treatment is real, but it isn’t unique to these drugs. Any time someone loses a lot of weight quickly — through diet, surgery, or medication — some muscle comes off along with fat. This has always been true.
The muscle loss looks proportional, not selective, for most people. The drugs don’t appear to specifically target muscle. Instead, muscle shrinks somewhat as part of an overall shrinking body, while fat — especially the fat stored around organs — tends to shrink more.
Individual results vary a lot. Age, how much muscle someone had to begin with, how much protein they eat, and whether they do any strength-building exercise all appear to change how much muscle is protected.

What this means for blood sugar, weight, and metabolic health

Here’s the part that doesn’t get enough attention: muscle isn’t just for strength. It’s one of the most important tools your body has for controlling blood sugar.

When you eat a meal with carbs, your blood sugar rises, and insulin’s job is to move that sugar out of your blood and into your cells for storage or energy.

Most of that sugar — somewhere around two-thirds of it in typical conditions, and even more under lab testing conditions — goes straight into your skeletal muscle.

Muscle is like a sponge for blood sugar. The more muscle you have, and the better that muscle works, the easier it is for your body to keep blood sugar in a healthy range without needing extra insulin to do it.

This is also why losing muscle isn’t just a cosmetic issue. Research on aging shows that people with less muscle tend to have a harder time controlling blood sugar, and the reverse is also true — people with poorly controlled blood sugar tend to lose muscle faster than people whose blood sugar is well managed.

It runs in both directions, like two problems feeding each other. One long-running study found that people with diabetes are about three times more likely to develop significant age-related muscle loss than people without diabetes.

It’s not just the amount of muscle that matters, either. Fat that builds up inside muscle cells appears to interfere with how well that muscle responds to insulin, even in someone who technically has “enough” muscle. Quantity and quality both count.

Practical implications

This is where the muscle story and the GLP-1 story connect directly. If muscle helps control blood sugar, and rapid weight loss can shrink muscle somewhat, then protecting muscle during weight loss isn’t just about looking toned — it may help preserve the very blood-sugar benefits that many people are taking these drugs to get in the first place.

The encouraging part: the two things known to help protect muscle during weight loss are things anyone can do, with or without a GLP-1 drug — eating enough protein, and doing some form of resistance exercise.

What we know

Skeletal muscle handles a large majority of the glucose your body clears after eating, based on decades of controlled testing.
People with diabetes lose muscle faster than people without it, and low muscle mass is linked to worse blood sugar control.
Some loss of lean tissue happens with any major, fast weight loss — GLP-1 drugs included.
Combining resistance exercise with adequate protein intake is consistently linked to better preservation of muscle during weight loss, based on multiple clinical trials.
Resistance training on its own has been shown, across dozens of randomized trials, to modestly improve blood sugar control in people with type 2 diabetes.

What we don’t know

Researchers don’t yet have long-term data on whether the muscle lost during years of GLP-1 treatment leads to real-world problems, like falls or loss of independence, later in life.
It isn’t fully clear which specific people are most at risk — the debate among doctors is really a debate about which warning signs matter most.
Better, more precise tools for measuring muscle (rather than just “lean mass,” which includes water and organs) are still being developed, which makes some of today’s numbers rougher estimates than they’ll eventually become.

Common misconceptions

“GLP-1 drugs specifically destroy muscle.” The research doesn’t support this. Muscle loss during treatment looks proportional to overall weight loss, not a targeted side effect of the drug attacking muscle tissue.

“If I’m not on a GLP-1 drug, muscle and blood sugar have nothing to do with me.” The opposite is true — the muscle-blood sugar connection applies to everyone, on any weight-loss plan or none at all. It’s just gotten more attention lately because of the GLP-1 conversation.

“More muscle mass always means better blood sugar control, no matter what.” Not quite. The quality of the muscle — how much fat has built up inside the muscle fibers themselves — also affects how well it responds to insulin. Someone can have a lot of muscle that isn’t functioning at its best.

Who should be particularly concerned

Based on current research, a few groups appear to warrant closer attention from their care team during weight loss, whether or not a GLP-1 drug is involved:

Older adults, who typically start with less muscle mass and reserve to begin with.
People who are losing weight unusually fast, or who are eating very little overall.
People who already have low muscle mass or diagnosed sarcopenia before starting treatment.
People with low protein intake or limited ability to be physically active, such as due to joint pain or mobility limits.

This is general, educational information, not a personal risk assessment — anyone in these groups who is concerned should bring it up with their doctor.

Practical, evidence-based recommendations

Prioritize protein at meals. Multiple research groups, including expert nutrition panels, note that intakes somewhat above the standard baseline recommendation are associated with better muscle preservation during weight loss, particularly in older adults. Exact needs vary by body size and health status, so this is worth a conversation with a doctor or registered dietitian rather than a one-size-fits-all number.
Add resistance exercise, even in small amounts. Bodyweight exercises, resistance bands, or weight training two to three times a week have been linked in clinical trials to better preserved muscle and, independently, to improved blood sugar control.
Don’t chase the fastest possible weight loss. Very rapid loss appears to carry a higher risk of losing lean tissue along with fat.
Track more than the number on the scale, if possible — strength, mobility, and how you feel doing daily tasks are meaningful signals that a number alone won’t show.
Bring this topic to your prescribing doctor directly if you’re on or considering a GLP-1 medication — this is a normal, well-documented conversation to have, not an unusual one.

Frequently asked questions

Does everyone lose muscle on GLP-1 drugs?

Some degree of lean tissue loss appears common during any significant weight loss, GLP-1-related or not. The amount varies widely between individuals.

Is muscle loss on these drugs dangerous?

For most people studied so far, there’s no clear evidence linking it to disability or frailty. Researchers agree the picture may be different for people who start with low muscle reserves, particularly older adults.

Can I prevent muscle loss while losing weight?

You can’t eliminate it entirely, but eating enough protein and doing resistance exercise are consistently linked to better-preserved muscle during weight loss in research so far.

Does this mean I should stop or avoid GLP-1 drugs?

This article isn’t medical advice, and decisions about starting, continuing, or stopping any medication should be made with your own doctor, based on your full health picture.

Why does muscle matter for blood sugar if I’m not trying to lose weight?

Muscle is one of the body’s main storage sites for blood sugar after meals, regardless of your weight or whether you’re on any medication. Keeping muscle active and healthy is a blood-sugar strategy in its own right.

Conclusion

The debate over GLP-1 drugs and muscle loss isn’t really a story about one class of medication — it’s a reminder of something that applies to everyone. Muscle is one of the body’s most important tools for managing blood sugar, and it’s worth protecting during any kind of weight loss, not just the kind that comes in a weekly injection. The current evidence suggests the risk is real but manageable for most people, with some groups warranting extra attention. As researchers gather longer-term data, the practical steps that help right now — eating enough protein, staying active, and talking openly with your doctor — are the same ones that have helped for decades.

References

Medscape (2026). Coverage of the ADA 2026 debate on GLP-1 drugs and muscle loss, and a narrative review on incretin mimetic therapy and muscle/bone health. [Ref]
Langer, H.T., et al. Cell Reports Medicine (2026). Study on GLP-1 medicines, lean body mass, and muscle function in mice and humans.
Mass General Brigham, Advances in Motion (2025). Grand rounds summary on preserving lean body mass during GLP-1 treatment.
DiaTribe (2024). Reporting on the link between diabetes and age-related muscle loss (sarcopenia).
Peer-reviewed research on skeletal muscle’s role in whole-body insulin-stimulated glucose disposal, including sex-comparative studies.
Systematic review and meta-analysis of randomized controlled trials on resistance training and HbA1c/fasting glucose in type 2 diabetes (2024).
Dose-response meta-analysis of resistance training in type 2 diabetes (2023).
Research on protein intake and lean mass preservation in adults with overweight/obesity, and in older adults with sarcopenia.